Increased N-terminal cleavage of alpha-2-antiplasmin in patients with liver cirrhosis

Journal of Thrombosis and Haemostasis

Volumn 11, Issue 11, 2013, Pages 2029-2036

  Uitte de Willige, S ^a   Malfliet, J J M C ^a   Janssen, H L A ^a   Leebeek, F W G ^a   Rijken, D C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Alpha 2 antiplasmin; Case control study; Fibrinolysis; Fibrosis; Liver cirrhosis

Indexed keywords

ALPHA 2 ANTIPLASMIN; ANTITHROMBIN; APROTININ; FIBRINOGEN; GENOMIC DNA; PLASMINOGEN; THROMBIN; TISSUE PLASMINOGEN ACTIVATOR; ANTIGEN; GELATINASE; MEMBRANE PROTEIN; PROTEIN BINDING; RECOMBINANT PROTEIN; SEPRASE; SERINE PROTEINASE;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; EUGLOBULIN LYSIS TEST; FEMALE; FIBRINOLYSIS; GENOTYPE; HETEROZYGOTE; HOMOZYGOTE; HUMAN; LIVER CIRRHOSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; ADOLESCENT; BLOOD; CASE CONTROL STUDY; CHEMISTRY; FIBROSIS; METABOLISM; MIDDLE AGED; PROTEIN TERTIARY STRUCTURE; SINGLE NUCLEOTIDE POLYMORPHISM; SOLUBILITY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALPHA-2-ANTIPLASMIN; ANTIGENS; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; FIBROSIS; GELATINASES; GENOTYPE; HUMANS; LIVER CIRRHOSIS; MALE; MEMBRANE PROTEINS; MIDDLE AGED; PLASMINOGEN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN BINDING; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SERINE ENDOPEPTIDASES; SOLUBILITY; YOUNG ADULT;

EID: 84887513588     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.12396     Document Type: Article

References (25)

1. Moroi M, Aoki N. Isolation and characterization of alpha2-plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 1976; 251: 5956-65.
2. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-16.
3. Sumi Y, Ichikawa Y, Nakamura Y, Miura O, Aoki N. Expression and characterization of pro alpha 2-plasmin inhibitor. J Biochem 1989; 106: 703-7.
4. Holmes WE, Nelles L, Lijnen HR, Collen D. Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 1987; 262: 1659-64.
5. Kluft C, Los P, Jie AF, van Hinsbergh VW, Vellenga E, Jespersen J, Henny CP. The mutual relationship between the two molecular forms of the major fibrinolysis inhibitor alpha-2-antiplasmin in blood. Blood 1986; 67: 616-22.
6. Clemmensen I, Thorsen S, Mullertz S, Petersen LC. Properties of three different molecular forms of the alpha 2 plasmin inhibitor. Eur J Biochem 1981; 120: 105-12.
7. Kluft C, Los P, Jie AF. The molecular form of alpha 2-antiplasmin with affinity for plasminogen is selectively bound to fibrin by factor XIII. Thromb Res 1984; 33: 419-25.
8. Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783-8.
9. Bangert K, Johnsen AH, Christensen U, Thorsen S. Different N-terminal forms of alpha 2-plasmin inhibitor in human plasma. Biochem J 1993; 291: 623-5.
10. Christiansen VJ, Jackson KW, Lee KN, McKee PA. The effect of a single nucleotide polymorphism on human (alpha) 2-antiplasmin activity. Blood 2007; 109: 5286-92.
11. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107: 1397-404.
12. Wang XM, Yao TW, Nadvi NA, Osborne B, McCaughan GW, Gorrell MD. Fibroblast activation protein and chronic liver disease. Front Biosci 2008; 13: 3168-80.
13. Levy MT, McCaughan GW, Marinos G, Gorrell MD. Intrahepatic expression of the hepatic stellate cell marker fibroblast activation protein correlates with the degree of fibrosis in hepatitis C virus infection. Liver 2002; 22: 93-101.
14. Uitte de Willige S, Miedzak M, Carter AM, Lisman T, Rosendaal FR, Grant PJ, Philippou H, Ariens RA. Proteolytic and genetic variation of the alpha-2-antiplasmin C-terminus in myocardial infarction. Blood 2011; 117: 6694-701.
15. Rijken DC, Kock EL, Guimarães AH, Talens S, Murad SD, Janssen HL, Leebeek FW. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116-22.
16. Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC, Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60: 646-9.
17. Livak KJ. Allelic discrimination using fluorogenic probes and the 5' nuclease assay. Genet Anal 1999; 14: 143-9.
18. Guimarães AH, de Bruijne EL, Lisman T, Dippel DW, Deckers JW, Poldermans D, Rijken DC, Leebeek FW. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145: 115-20.
19. Rijken DC, Hoegee-de Nobel E, Jie AF, Atsma DE, Schalij MJ, Nieuwenhuizen W. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 2008; 6: 151-7.
20. Aoki N, Yamanaka T. The alpha2-plasmin inhibitor levels in liver diseases. Clin Chim Acta 1978; 84: 99-105.
21. Leebeek FWG, Kluft C, Knot EAR, De Maat MPM. Inappropriate inhibition at the plasmin level may contribute to enhanced fibrinolysis in advanced liver cirrhosis. Fibrinolysis 1988; 2: 75-8.
22. Leebeek FWG, Kluft C, Knot EAR, de Maat MPM, Wilson JH. A shift in balance between profibrinolytic and antifibrinolytic factors causes enhanced fibrinolysis in cirrhosis. Gastroenterology 1991; 101: 1382-90.
23. Lisman T, Leebeek FW. Hemostatic alterations in liver disease: a review on pathophysiology, clinical consequences, and treatment. Dig Surg 2007; 24: 250-8.
24. Freund KF, Doshi KP, Gaul SL, Claremon DA, Remy DC, Baldwin JJ, Pitzenberger SM, Stern AM. Transglutaminase inhibition by 2-[(2-oxopropyl)thio]imidazolium derivatives: mechanism of factor XIIIa inactivation. Biochemistry 1994; 33: 10109-19.
25. Mutch NJ, Koikkalainen JS, Fraser SR, Duthie KM, Griffin M, Mitchell J, Watson HG, Booth NA. Model thrombi formed under flow reveal the role of factor XIII-mediated cross-linking in resistance to fibrinolysis. J Thromb Haemost 2010; 8: 2017-24.